Poland· PL-100463978

Novain

A oxybuprocaine product containing oxybuprocaini hydrochloridum, registered in Poland by AGEPHA Pharma s.r.o.. The same ATC class is registered in 11 of our 19 countries.

ATC S01HA02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedNovainATCS01HA02REGISTER NO.PL-100463978PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Oxybuprocaine is registered in 11 of 19 countries.

Countries holding a registration under ATC S01HA02 (oxybuprocaine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose

Oxybuprocaine · ATC S01HA02

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Oxybuprocaini hydrochloridum
Manufacturer
AGEPHA Pharma s.r.o.
Country
Poland (PL)
ATC code
S01HA02
ATC class
Oxybuprocaine
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991516765

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

40 interactions on record for oxybuprocaine.

Graded by severity as the source publishes them — 40 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Oxybuprocaine · interactions on record

40 records

  • 40 moderate

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • SulfamethizoleB05CA04moderate
  • LidocaineC01BB01moderate
  • Glyceryl trinitrateC01DA02moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Oxybuprocaine in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All oxybuprocaine products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

  • Austria · Benoxinat Zur Anästhesie In Der Oto-Rhino-Laryngologie, Novain
  • Belgium · Minims Oxybuprocaine Chlorhydrate Bausch + Lomb Ireland Limited, Minims Oxybuprocaïnehydrochloride Bausch + Lomb Ireland Limited
  • Bulgaria · Бенокси
  • Czechia · Benoxi, Oxybuprocaine Olikla
  • Germany · Conjuncain® Edo®, Novesine
  • Denmark · Oftasen, Oxybuprocainhydrochlorid Agepha
  • Estonia · Novain
  • Spain · Oxibuprocaína Hidrocloruro Agepha
  • Finland · Minims, Obupro 4 Mg/Ml Silmätipat, Liuos
  • France · Cebesine, Chlorhydrate D’oxybuprocaine Thea
  • United Kingdom (Northern Ireland) · Oxybuprocaine Hydrochloride Alfa Intes
  • Croatia · Ophtesia
  • Hungary · Humacain, Oxybuprocaine Hydrochloride Agepha
  • Ireland · Oxybuprocaine Agepha
  • Iceland · Novain
  • Italy · Benoxinato Cloridrato Intes, Novesina
  • Lithuania · Novain
  • Luxembourg · Conjuncain Edo, Minims
  • Latvia · Oxybuprocaine Hydrochloride Agepha 4 Mg/Ml
  • Netherlands · Minims, Monofree
  • Norway · Obupro, Oxibuprokain Minims Bausch + Lomb Ireland Limited
  • Portugal · Anestocil, Novain 4 Mg/Ml Colírio,
  • Romania · Benoxi, Oftacain
  • Sweden · Novain, Oxibuprokain Bausch & Lomb
  • Slovakia · Benoxi, Oxybuprocaine Olikla

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b6e66d84-158b-47d0-a024-e6f8c4d3c9e4
GET /v1/drugs/b6e66d84-158b-47d0-a024-e6f8c4d3c9e4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Krople do oczu, roztwór",
  "source": "urpl",
  "strength": "4 mg/ml",
  "packaging": "05909991516765 ¦ Rpz ¦ 150435\n1 butelka 10 ml",
  "substance": "Oxybuprocaini hydrochloridum 4 mg/ml",
  "common_name": "Oxybuprocaini hydrochloridum",
  "pl_product_id": "100463978",
  "pozwolenie_nr": "27901",
  "auth_procedure": "MRP",
  "authorisation_validity": "2028-06-29"
}

See everything about oxybuprocaine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.